La catena delle opzioni mostra i dati chiave delle opzioni azionarie di JW (Cayman) Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per JW (Cayman) Therapeutics..

JW (Cayman) Therapeutics (OTC:JWCTF) Azioni, Catena delle Opzioni

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW CAYMAN THERAPEUTICS CO by JW CAYMAN THERAPEUTICS CO LTD.

JW (Cayman) Therapeutics Co Ltd

News

LSEA

Apollo Global Management Portfolio Company, New Home Co. Has Entered Into A Definitive Agreement Under Which It Will Acquire Landsea Homes For $11.30 Per Share In An All-Cash Transaction

OptimumBank Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPHC#NASDAQ">OPHC</a>) reported quarterly earnings of $0.32 per share. This is a 3.23 percent increase over earnings of $0.31 per share from the same period last year. The company reported $10.66 million in sales this quarter. This is a 18.54 percent increase over sales of $8.99 million the same period last year.

Earnings

OPHC

OptimumBank Hldgs Q1 EPS $0.32 Up From $0.31 YoY, Sales $10.66M Up From $8.99M YoY

New Found Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NFGC#AMEX">NFGC</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 40 percent increase over losses of $(0.05) per share from the same period last year.

Earnings Beats

NFGC

New Found Gold Q1 GAAP EPS $(0.03) Beats $(0.06) Estimate

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $24 to $27.

Price Target

Analyst Ratings

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $27

Barclays analyst Theresa Chen maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Equal-Weight and raises the price target from $106 to $115.

Barclays Maintains Equal-Weight on Phillips 66, Raises Price Target to $115

ORIX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IX#NYSE">IX</a>) reported quarterly earnings of $0.46 per share. This is a 37.84 percent decrease over earnings of $0.74 per share from the same period last year. The company reported $4.72 billion in sales this quarter. This is a 9.75 percent decrease over sales of $5.23 billion the same period last year.

ORIX Q4 EPS $0.46 Down From $0.74 YoY, Sales $4.72B Down From $5.23B YoY

Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 75.57 percent increase over losses of $(1.31) per share from the same period last year.

BBLG

Bone Biologics Q1 EPS $(0.32) Beats $(0.48) Estimate

Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) reported $85.17 million in sales this quarter. This is a 69.57 percent increase over sales of $50.23 million the same period last year.

Morgan Stanley Market Vectors Rupee/USD ETN

Infinity Natural Q1 Sales $85.17M Up From $50.23M YoY

Barclays analyst Theresa Chen maintains MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) with a Overweight and lowers the price target from $55 to $52.

MPLX

Barclays Maintains Overweight on MPLX, Lowers Price Target to $52

Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.41) by 36.59 percent. This is a 92.95 percent increase over losses of $(3.69) per share from the same period last year.

GNPX

Genprex Q1 EPS $(0.26) Beats $(0.41) Estimate

Barclays analyst Lauren Lieberman maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Equal-Weight and lowers the price target from $60 to $57.

Barclays Maintains Equal-Weight on Molson Coors Beverage, Lowers Price Target to $57

Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.70) by 32.86 percent. This is a 89.76 percent increase over losses of $(4.59) per share from the same period last year.

PALI

Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Getty Images Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) reported first-quarter financial results Monday after the close. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/g45359438/getty-images-reports-first-quarter-2025-results">from the print</a>.
Q1 Earnings: Getty Images reported first-quarter revenue of $224.08 million, missing analyst <a href="http://benzinga.com/quote/gety/estimates">estimates</a> of $236.01 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter adjusted loss of 14 cents per share.
Total revenue was up 0.8% year-over-year and annual subscription revenue climbed 5.4% year-over-year. Here&#8217;s a breakdown of revenue by category:
<ul class="wp-block-list">
<li>Creative revenue: $132.3 million, down 4.8%</li>
</ul>
<ul class="wp-block-list">
<li>Editorial revenue: $82.6 million, up 4% </li>
</ul>
Getty Images generated cash flow from operations of $15.4 million and reported negative free cash flow of $300,000. The company ended the quarter with $114.6 million in cash.
&#8220;Results in the&nbsp;first quarter&nbsp;were consistent with our expectations, with growth highlighted by gains across our subscription business, and continued customer value delivered through our offerings,&#8221; said Craig Peters, CEO of Getty Images. 
&#8220;We remain committed to investing in the core assets of our company and continuing to evolve our offering in ways that deepen our relevance for our customers. We believe this strategy positions us well to achieve our 2025 outlook and beyond.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">NuScale Power Reports Q1 Results: Details</a>
Guidance: Getty raised its full-year 2025 revenue guidance from a range of $918 million to $955 million to a new range of $931 million to $968 million. Analysts are forecasting full-year revenue of $942.67 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Getty Images noted that it continues to work cooperatively with the U.S. Department of Justice and other non-U.S. regulators to obtain regulatory clearance for its proposed merger with Shutterstock.
GETY Price Action: <a href="http://benzinga.com/quote/gety">Getty Images shares</a> were down 1.99% in after-hours, trading at $1.97 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/brodogg1313">Eric Broder Van Dyke</a>/Shutterstock.

Guidance

After-Hours Center

Movers

Media

GETY

Getty Images Reports Q1 Results Below Estimates, Raises FY25 Guidance, Shares Slide

SK Telecom Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKM#NYSE">SKM</a>) reported quarterly earnings of $0.65 per share. This is a 4.41 percent decrease over earnings of $0.68 per share from the same period last year. The company reported $3.07 billion in sales this quarter. This is a 8.80 percent decrease over sales of $3.37 billion the same period last year.

SK Telecom Co Q1 EPS $0.65 Down From $0.68 YoY, Sales $3.07B Down From $3.37B YoY

eXoZymes Inc. - Common Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) reported quarterly losses of $(0.22) per share. This is a 37.5 percent decrease over losses of $(0.16) per share from the same period last year.

EXOZ

eXoZymes Inc. - Common Stock Q4 EPS $(0.22) Down From $(0.16) YoY

Management

PROV

Provident Financial Holdings Appoints Peter C. Fan As  Chief Financial Officer, Effective May 12, 2025

Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) reported quarterly earnings of $0.01 per share. This is a 105.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported $135.00 thousand in sales this quarter. This is a 33.52 percent decrease over sales of $203.06 thousand the same period last year.

OMEX

Odyssey Marine Explr Q1 EPS $0.01 Up From $(0.18) YoY, Sales $135.00K Down From $203.06K YoY

Barclays analyst Ramsey El-Assal maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Equal-Weight and raises the price target from $4 to $5.

Barclays Maintains Equal-Weight on Marqeta, Raises Price Target to $5

Paramount Gold Nevada (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PZG#AMEX">PZG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year.

Earnings Misses

Paramount Gold Nevada Q3 GAAP EPS $(0.04) Misses $(0.02) Estimate

Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.49) by 10.07 percent. This is a 7.34 percent increase over losses of $(1.77) per share from the same period last year.

Comments

JW (Cayman) Therapeutics

JW (Cayman) Therapeutics (JWCTF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO